Summary
Zoetis Inc. (ZTS) announced on December 21, 2015, the signing of an asset purchase agreement with Huvepharma to divest three manufacturing and distribution sites located in Laurinburg, North Carolina; Longmont, Colorado; and Van Buren, Arkansas. This divestment also includes a portfolio of products primarily associated with these sites, such as medicated feed additives, water-soluble therapeutics, and nutritionals for livestock. The transaction is expected to close in the first quarter of 2016. This strategic move is part of Zoetis's broader operational efficiency program initiated in May 2015. The program aims to streamline operations, optimize resource allocation, and ultimately foster long-term profitable growth. By divesting these specific lower-revenue, lower-margin product lines and associated manufacturing capabilities, Zoetis intends to enhance its overall profitability and improve the efficiency and reliability of its supply chain network. While the transaction is not considered material to Zoetis Inc. as a whole, it signifies a focused effort to refine its business and focus on core, higher-margin opportunities.
Key Highlights
- 1Zoetis is divesting three U.S. manufacturing/distribution sites (Laurinburg, NC; Longmont, CO; Van Buren, AR) to Huvepharma.
- 2The divestment includes a portfolio of livestock products, mainly medicated feed additives, water-soluble therapeutics, and nutritionals.
- 3Zoetis will receive $40 million in cash and additional considerations as part of the agreement.
- 4Employees at the affected sites will transfer to Huvepharma.
- 5The transaction is part of Zoetis's broader operational efficiency program to reduce complexity and optimize resource allocation.
- 6The divested products are characterized as lower-revenue and lower-margin, with their elimination intended to improve company profitability.
- 7The transaction is expected to be completed in the first quarter of 2016.